<DOC>
	<DOCNO>NCT00196846</DOCNO>
	<brief_summary>Study do young breast cancer patient prevent chemotherapy induced ovarian failure</brief_summary>
	<brief_title>Prevention Chemotherapy Induced Ovarian Failure With Goserelin BC Patients ( ZORO )</brief_title>
	<detailed_description>Study Design : Prospective , randomize , open phase II trial Schedule : All patient receive anthracycline-containing polychemotherapy . Patients randomized Goserelin receive first injection 3.6 mg least 2 week start chemotherapy . Goserelin give subcutaneous injection abdominal wall every 4 week ( 28 ± 3 day ) end last chemotherapy cycle . Primary objective : •To increase percentage patient normal ovarian function 6 month application ( neo ) adjuvant , anthracycline-containing polychemotherapy parallel Goserelin compare chemotherapy alone . Secondary objective : To compare two treatment group regard - Compliance treatment - Toxicity - Quality life - Menopausal Symptoms Score - Ovarian function 6 , 12 , 18 24 month - Duration recovery regular menstrual period - Pregnancy rate</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>Written informed consent must obtain document accord local regulatory requirement prior begin specific protocol procedure Complete baseline documentation send GBG Age least 18 45 year Patients request preserve ovarian function Spontaneous regular menstrual period study entry FSH 15 mlU/ml follicular phase Histologically confirm primary breast cancer need anthracyclinebased chemotherapy Steroid receptor ( estrogen progesterone ) negative tumor ( diagnosis accord hospital standardprocedures ) No clinical evidence local recurrence distant metastasis . Complete stag workup within 3 month prior registration . All patient must ( bilateral ) mammography breast MRI , chest Xray ; test may perform clinically indicated KarnofskyIndex &gt; 80 % Life expectancy least 10 year , disregard diagnosis cancer Adequate organ function include normal red white blood count , platelet , serum creatinine , bilirubin , transaminase within normal range institution Patients must available compliant treatment followup . Patients register trial must treat follow participate center . Known hypersensitivity reaction investigational compound incorporated substance Prior cytotoxic treatment reason Suspected ( primary secondary ) ovarian insufficiency Pregnant lactating patient . Patients childbearing potential must negative pregnancy test ( urine serum ) within 14 day prior registration must implement adequate nonhormonal contraceptive measure study treatment ; prior use hormonal contraceptive discontinue first Goserelin injection Other serious illness medical condition may interfere understand give informed consent conduct study Prior concomitant secondary malignancy ( except nonmelanomatous skin cancer carcinoma situ uterine cervix ) Concurrent treatment experimental drug anticancer therapy Concurrent treatment sex hormone . Prior treatment must stop study entry</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>hormone insensitive breast cancer</keyword>
	<keyword>Prevention Chemotherapy induce ovarian failure</keyword>
	<keyword>P.O.F .</keyword>
	<keyword>GnRH-Agonist Goserelin</keyword>
</DOC>